1. Ferlay J, Ervik M, Lam F, et al. Global cancer observatory: cancer today. International Agency for Research on Cancer, Lyon 2020.
2.
Assessing national capacity for the prevention and control of non-communicable diseases: report of the 2019 global survey. World Health Organization, Geneva 2020.
3.
Park BJ, Yang HX, Woo KM, Sima CS. Minimally invasive (robotic- assisted thoracic surgery and video-assisted thoracic surgery) lobectomy for the treatment of locally advanced non-small cell lung cancer. J Thorac Dis 2016; 8: S406-S408.
4.
De Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Global Health 2020; 8: e180-e190.
5.
Xia R, Xu G, Huang Y, Sheng X, Xu X, Lu H. Hesperidin suppresses the migration and invasion of non-small cell lung cancer cells by inhibiting the SDF-1/CXCR-4 pathway. Life Sci 2018; 201: 111-120.
6.
Kuntić V, Pejić N, Micić S. Direct spectrophotometric determination of hesperidin in pharmaceutical preparations. Acta Chimica Slovenica 2012; 59: 436-441.
7.
Kamaraj S, Ramakrishnan G, Anandakumar P, Jagan S, Devaki T. Antioxidant and anticancer efficacy of hesperidin in benzo(A)pyrene induced lung carcinogenesis in mice. Invest New Drugs 2008; 27: 214-22.
8.
Aggarwal M, Grady A, Desai D, et al. Successful implementation of healthful nutrition initiatives into hospitals. Am J Med 2020; 133: 19-25.
9.
Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 2002; 99: 12293-12297.
10.
Lin C, Chen X, Li M, et al. Programmed death-ligand 1 expression predicts tyrosine kinase inhibitor response and better prognosis in a cohort of patients with epidermal growth factor receptor mutation-positive lung adenocarcinoma. Clin Lung Cancer 2015; 16: e25-e35.
11.
Elanany MM, Mostafa D, Hamdy NM. Remodeled tumor immune microenvironment (TIME) parade via natural killer cells reprogramming in breast cancer. Life Sci 2023; 330: 121997.
12.
Zhang Y, Wang L, Li Y, et al. A Comprehensive investigation of molecular features and prognosis of lung adenocarcinoma with micropapillary component. J Thor Oncol 2014; 9: 1772-1778.
13.
Ikeda S, Okamoto T, Okano S, et al. PD-L1 is upregulated by simultaneous amplification of the PD-L1 and JAK2 genes in non–small cell lung cancer. J Thor Oncol 2016; 11: 62-71.
14.
Ibrahim SM, Fayez AM, Maher A. Mesenchymal stromal cells suppress hepatic fibrosis via modulating expression of fibronectin and integrin and inhibiting DNA fragmentation in rats. Available from: https://www.archivesofmedicalscience.com/Mesenchymal-stromal-cells-suppress-hepatic-fibrosis-via-modulating-expression-of,134826,0,2.html.
15.
Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192: 1027-1034.
16.
Nadia M. Hamdy. Relationship between pro-anti-inflammatory cytokines, T-cell activation and CA 125 in obese patients with heart failure. Med Sci Monit 2011; 17: CR174-179.
17.
Hamdy NM, El-Wakeel L, Suwailem SM. Involvement of depressive catecholamines as thrombosis risk/inflammatory markers in non-smoker, non-obese congestive heart failure, linked to increased epidermal growth factor-receptor (EGF-R) production. Indian J Clin Biochem 2011; 26: 140-145.
18.
Mak MP, William JrWN. Targeting the epidermal growth factor receptor for head and neck cancer chemoprevention. Oral Oncol 2014; 50: 918-923.
19.
Wang Z. Transactivation of epidermal growth factor receptor by G protein-coupled receptors: recent progress, challenges, and future research. Inte J Mol Sci 2016; 17: 95.
20.
Mo’men YS, Hussein RM, Kandeil MA. Involvement of PI3K/Akt pathway in the protective effect of hesperidin against a chemically induced liver cancer in rats. J Biochem Mol Toxicol 2019; 33: e22305.
21.
Mahmoud MM, Sanad EF, Hamdy NM. MicroRNAs’ role in the environment-related non-communicable diseases and link to multidrug resistance, regulation, or alteration. Environ Sci Pollut Res Int 2021; 28: 36984-37000.
22.
Mahmoud MM, Sanad EF, Elshimy RAA, Hamdy NM. Competitive endogenous role of the LINC00511/miR-185-3p axis and miR-301a-3p from liquid biopsy as molecular markers for breast cancer diagnosis. Front Oncol 2021; 11: 749753.
23.
Reid G, Kao SC, Pavlakis N, et al. Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer. Epigenomics 2016; 8: 1079-1085.
24.
Takagawa Y, Gen Y, Muramatsu T, et al. MiR-1293, a candidate for miRNA-based cancer therapeutics, simultaneously targets BRD4 and the DNA repair pathway. Mol Ther 2020; 28: 1494-1505.
25.
Zhang LZ, Yang JE, Luo YW, Liu FT, Yuan YF, Zhuang SM. A p53/lncIp53 negative feedback loop regulates tumor growth and chemoresistance. Adv Sci 2020; 7: 2001364.
26.
Kwok GT, Zhao JT, Weiss J, et al. Translational applications of microRNAs in cancer, and therapeutic implications. Noncoding RNA Res 2017; 2: 143-150.
27.
Shi J, Zhao Y, Wang Y, et al. Inflammatory caspases are innate immune receptors for intracellular LPS. Nature 2014; 514: 187-192.
28.
Pasparakis M. Role of NF-B in epithelial biology. Immunol Rev 2012; 246: 346-358.
29.
Cooks T, Pateras IS, Tarcic O, et al. Mutant p53 prolongs NF-B activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell 2013; 23: 634-646.
30.
Gilmore TD, Garbati MR. Inhibition of NF-B signaling as a strategy in disease therapy. In: Karin E (ed.). NF-kB in health and disease. Springer, Berlin 2010, 245-263.
31.
Allam RM, Al-Abd AM, Khedr A, Sharaf OA. Fingolimod interrupts the cross-talk between estrogen metabolism and sphingolipid metabolism within prostate cancer cells. Toxicol Lett 2018; 291: 77-85.
32.
Fekry MI, Ezzat SM, Salama MM, Alshehri OY, Al-Abd AM. Bioactive glycoalkaloids isolated from Solanum melongena fruit peels with potential anticancer properties against hepatocellular carcinoma cells. Sci Rep 2019; 9: 1746.
33.
Martinotti S, Ranzato E. Scratch wound healing assay. In: Turksen K. Epidermal cells. Methods in molecular biology, Springer, Berlin 2019, 2109.
34.
Andriani F, Perego P, Carenini N, Sozzi G, Roz L. Increased sensitivity to cisplatin in non-small cell lung cancer cell lines after FHIT gene tran neoplasia. Neoplasia 2006; 8: 9-17.
35.
Perego P, Beretta G, Gatti L. Identification of determinants of sensitivity to antitumor drugs. In: Conn PM (ed.). Handbook of proteomic methods. Humana Press Inc., Totowa, NJ 2003, 319-331.
36.
Choi YM, Kim HK, Shim W, et al. Mechanism of cisplatin-induced cytotoxicity is correlated to impaired metabolism due to mitochondrial ROS generation. PLoS One 2015; 10: e0135083.
37.
Xia R, Sheng X, Xu X, Yu C. Lu H. Hesperidin induces apoptosis and G0/G1 arrest in human non-small cell lung cancer A549 cells. Int J Mol Med 2018; 41: 464-472.
38.
Hafez MM, Abdel-Hafez LM, Jamil L, Ibrahim SM. Association between cluster of differentiation 24 (CD24) polymorphism, talin-1 gene expression and hepatocellular carcinoma prevalence in the Egyptian population. Available from: https://www.archivesofmedicalscience.com/Association-between-cluster-of-differentiation-24-CD24-polymorphism-talin-1-gene,140451,0,2.html.
39.
Longchar A, Prasad SB. Biochemical changes associated with ascorbic acid-cisplatin combination therapeutic efficacy and protective effect on cisplatin-induced toxicity in tumor-bearing mice. Toxicol Rep 2015; 7: 489-503.
40.
Cragg GM, Pezzuto JM. Natural products as a vital source for the discovery of cancer chemotherapeutic and chemopreventive agents. Med Princ Pract 2016; 25: 41-59.
41.
Garg A, Garg S, Zaneveld LJD, Singla AK. Chemistry and pharmacology of the citrus bioflavonoid hesperidin. Phytother Res 2001; 15: 655-669.
42.
Parhiz H, Roohbakhsh A, Soltani F, Rezaee R, Iranshahi M. Antioxidant and anti-inflammatory properties of the citrus flavonoids hesperidin and hesperetin: an updated review of their molecular mechanisms and experimental models. Phytother Res 2015; 29: 323-331.
43.
Tanaka T, Makita H, Ohnishi M, et al. Chemoprevention of 4-nitroquinoline 1-oxide-induced oral carcinogenesis in rats by flavonoids diosmin and hesperidin, each alone and in combination. Cancer Res 1997; 57: 246-252.
44.
Birsu Cincin Z, Unlu M, Kiran B, Sinem Bireller E, Baran Y, Cakmakoglu B. Anti-proliferative, apoptotic, and signal transduction effects of hesperidin in non-small cell lung cancer cells. Cell Oncol 2015; 38: 195-204.
45.
Xia R, Xu G, Huang Y, Sheng X, Xu X, Lu H. Hesperidin suppresses the migration and invasion of non-small cell lung cancer cells by inhibiting the SDF-1/CXCR-4 pathway. Life Sci 2018; 201: 111-120.
46.
Reedijk J, Lohman, PHM. Cisplatin: synthesis, antitumor activity and mechanism of action. Pharm Weekbl Sci 1985; 7: 173-180.
47.
Rozengurt E. Autocrine loops, signal transduction, and cell cycle abnormalities in the molecular biology of lung cancer. Curr Opin Oncol 1999; 11: 116-122.
48.
Concato VM, Tomiotto-Pellissiera F, Silva TF, et al. 3,3’,5,5’-tetramethoxybiphenyl-4,4’diol induces cell cycle arrest in G2/M phase and apoptosis in human non -small cell lung cancer A549 cells. Chem Biol Interact 2020; 326: 109133.
49.
Kabała-Dzik A, Rzepecka-Stojko A, Kubina R, et al. Flavonoids, bioactive components of propolis, exhibit cytotoxic activity and induce cell cycle arrest and apoptosis in human breast cancer cells MDA-MB-231 and MCF-7 – a comparative study. Cell Mol Biol 2018; 64: 1-10.
50.
Bodduluru LN, Kasala ER, Barua CC, Karnam KC, Dahiya V, Ellutla M. Antiproliferative and antioxidant potential of hesperetin against benzo(a)pyrene-induced lung carcinogenesis in Swiss albino mice. Chem Biol Interact 2015; 242: 345-352.
51.
Aggarwal V, Tuli H, Thakral F, Singhal P, Aggarwal D, Srivastava S. Molecular mechanisms of action of hesperidin in cancer: Recent trends and advancements. Exp Biol Med (Maywood) 2020; 245: 486-497.
52.
Akbay EA, Koyama S, Carretero J, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 2013; 3: 1355-1363.
53.
Gong B, Kiyotani K, Sakata S, et al. Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer. J Exp Med 2019; 216: 982-1000.
54.
Wang Q, Lin W, Tang X, et al. The roles of microRNAs in regulating the expression of PD-1/PD-L1 immune checkpoint. Int J Mol Sci 2017; 18: 2540.
55.
Zhang Y, Yang P, Wang XF. Microenvironmental regulation of cancer metastasis by miRNAs. Trends Cell Biol 2014; 24: 153-160.
56.
Sun C, Mezzadra R, Schumacher TN. Regulation and Function of the PD-L1 checkpoint. Immunity 2018; 48: 434-452.
57.
Cortez MA, Ivan C, Valdecanas D, et al. PDL1 regulation by p53 via miR-34. J Natl Cancer Inst 2016; 108: djv303.
58.
Donia TIK, Gerges MN, Mohamed TM. Amelioration effect of Egyptian sweet orange hesperidin on Ehrlich ascites carcinoma (EAC) bearing mice. Chem Biol Interact 2018; 285: 76-84.
59.
Chang CJ, Chao CH, Xia W, et al. P53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol 2011; 13: 317-323.
60.
Xu S, Tao Z, Hai B, et al. MiR-424 (322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint. Nat Commun 2016; 7: 11406.
61.
Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of cisplatin nephrotoxicity. Toxins 2010; 2: 2490-2518.
62.
Aldossary SA. Review on pharmacology of cisplatin: clinical use, toxicity and mechanism of resistance of cisplatin. Biomed Pharmacol J 2019; 12: 7-15.
63.
Sahu BD, Kuncha M, Sindhura GJ, Sistla R. Hesperidin attenuates cisplatin-induced acute renal injury by decreasing oxidative stress, inflammation, and DNA damage. Phytomedicine 2013; 20: 453-460.
64.
Birsu Cincin Z, Unlu M, Kiran B, Sinem Bireller E, Baran Y, Cakmakoglu B. Anti-proliferative, apoptotic, and signal transduction effects of hesperidin in non-small cell lung cancer cells. Cell Oncol 2015; 38: 195-204.